Expression and significance of Pin1, β‑catenin and cyclin D1 in hepatocellular carcinoma

Ao,Ran; Zhang,Dao‑Rong; Du,Ya‑Qi; Wang,Ying

doi:10.3892/mmr.2014.2456

Expression and significance of Pin1, β‑catenin and cyclin D1 in hepatocellular carcinoma

Authors:
- Ran Ao
- Dao‑Rong Zhang
- Ya‑Qi Du
- Ying Wang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Pathophysiology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: August 6, 2014 https://doi.org/10.3892/mmr.2014.2456
Pages: 1893-1898

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the expression and significance of peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1), β‑catenin and cyclin D1 in hepatocellular carcinoma (HCC). A total of 24 samples of HCC and adjacent normal tissues were analyzed. The expression of Pin1, β‑catenin and cyclin D1 in HCC were detected using immunohistochemistry, western blot analysis, polymerase chain reaction and immunofluorescence. The expression of Pin1, β‑catenin and cyclin D1 in HCC tissues were significantly higher than that in adjacent tissues. Pin1 was not markedly expressed in the adjacent normal tissues, while expression in the cytoplasm and nucleus of HCC cells was high. However, β‑catenin and cyclin D1 only revealed a weak expression in the cytoplasm and nucleus of HCC cells. Immunoprecipitation analyses demonstrated two clear bands at 19 and 34 kDa, and a brown band at 55 kDa as expected. Immunofluorescence analysis of HCC cells indicated that Pin1 was present in the cytoplasm and nucleus, and β‑catenin and cyclin D1 were present in the nucleus. In conclusion, the present study indicated that Pin1, β‑catenin and cyclin D1 were highly expressed in HCC. Therefore, detection of the expression of Pin1, β‑catenin and cyclin D1 may be useful for the development of novel diagnostic and treatment strategies for HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Ascha MS, Hanouneh IA, Lopez R, et al: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI
3	Severi T, van Malenstein H, Verslype C and van Pelt JF: Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin. 31:1409–1420. 2010. View Article : Google Scholar : PubMed/NCBI
4	Liu Y, Pan S, Liu L, et al: A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PloS One. 7:e351452012. View Article : Google Scholar : PubMed/NCBI
5	Kang TW, Yevsa T, Woller N, et al: Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 479:547–551. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kanwal F, Hoang T, Kramer JR, et al: Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 140:1182–1188. 2011. View Article : Google Scholar : PubMed/NCBI
7	Nguyen VT, Law MG and Dore GJ: Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar
8	Nejak-Bowen KN, Thompson MD, Singh S, et al: Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology. 51:1603–1613. 2010. View Article : Google Scholar : PubMed/NCBI
9	Cheng CW, Chow AK, Pang R, et al: PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin. Am J Pathol. 182:765–775. 2013. View Article : Google Scholar : PubMed/NCBI
10	Abrahamsen H, O’Neill AK, Kannan N, et al: Peptidyl-prolyl isomerase Pin1 controls down-regulation of conventional protein kinase C isozymes. J Biol Chem. 287:13262–13278. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bao L, Kimzey A, Sauter G, et al: Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol. 164:1727–1737. 2004. View Article : Google Scholar : PubMed/NCBI
12	Aluise CD, Rose K, Boiani M, et al: Peptidyl-prolyl cis/trans-isomerase A1 (Pin1) is a target for modification by lipid electrophiles. Chem Res Toxicol. 26:270–279. 2013. View Article : Google Scholar : PubMed/NCBI
13	Tabarés-Seisdedos R and Rubenstein JL: Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci. 14:293–304. 2013.PubMed/NCBI
14	Lu KP and Zhou XZ: The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 8:904–916. 2007. View Article : Google Scholar : PubMed/NCBI
15	Teng BL, Hacker KE, Chen S, et al: Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Mol Oncol. 5:465–474. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pang RW, Lee TK, Man K, et al: PIN1 expression contributes to hepatic carcinogenesis. J Pathol. 210:19–25. 2006. View Article : Google Scholar : PubMed/NCBI
17	Maher MT, Flozak AS, Stocker AM, et al: Activity of the beta-catenin phosphodestruction complex at cell-cell contacts is enhanced by cadherin-based adhesion. J Cell Biol. 186:219–228. 2009. View Article : Google Scholar : PubMed/NCBI
18	Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
19	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012.
20	Stein TJ, Jochem A, Holmes KE and Sandgren EP: Effect of mutant β-catenin on liver growth homeostasis and hepatocarcinogenesis in transgenic mice. Liver Int. 31:303–312. 2011.
21	Zimmerman ZF, Moon RT and Chien AJ: Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol. Nov 1–2012.(Epub ahead of print).
22	Herr P, Hausmann G and Basler K: WNT secretion and signalling in human disease. Trends Mol Med. 18:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
23	Hayakawa Y, Hirata Y, Nakagawa H, et al: Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer. Proc Natl Acad Sci USA. 108:780–785. 2011. View Article : Google Scholar
24	Santarius T, Shipley J, Brewer D, et al: A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 10:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
25	Vaites LP, Lee EK, Lian Z, et al: The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol Cell Biol. 31:4513–4523. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wang C, Lisanti MP and Liao DJ: Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 10:57–67. 2011. View Article : Google Scholar : PubMed/NCBI
27	Parekh P, Motiwale L, Naik N and Rao KV: Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol. 63:167–173. 2011. View Article : Google Scholar : PubMed/NCBI
28	Huang S and He X: The role of microRNAs in liver cancer progression. Br J Cancer. 104:235–240. 2011. View Article : Google Scholar : PubMed/NCBI
29	Pang RW and Poon RT: Diagnosis: Novel prognostic biomarkers in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 9:691–692. 2012. View Article : Google Scholar : PubMed/NCBI
30	Xu GG and Etzkorn FA: Pin1 as an anticancer drug target. Drug News Perspect. 22:399–407. 2009. View Article : Google Scholar : PubMed/NCBI
31	Brembeck FH, Rosário M and Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 16:51–59. 2006. View Article : Google Scholar : PubMed/NCBI
32	Shen M, Stukenberg PT, Kirschner MW and Lu KP: The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev. 12:706–720. 1998. View Article : Google Scholar : PubMed/NCBI
33	Takahashi K, Uchida C, Shin RW, et al: Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer’s disease. Cell Mol Life Sci. 65:359–375. 2008.PubMed/NCBI
34	Inagawa S, Itabashi M, Adachi S, et al: Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 8:450–456. 2002.PubMed/NCBI
35	David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI